|
|
|
|
|
|
|
|
|
26.04.26 - 18:03
|
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 (GlobeNewswire EN)
|
|
|
MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.02.26 - 13:03
|
Oruka Therapeutics to Participate in Multiple Upcoming Conferences (GlobeNewswire EN)
|
|
|
MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences:...
|
|
|
|
|
06.01.26 - 13:03
|
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026....
|
|
|
|